Orbimed Advisors reduced stake in Oric Pharmaceuticals, Inc.

This post was originally published on this site


Orbimed Advisors’s holding in Oric Pharmaceuticals, Inc. decreased to about 2.2 million shares with the transaction.

Orbimed Advisors first bought Oric Pharmaceuticals, Inc. stock in the second quarter of 2020.
Orbimed Advisors also owns Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), Biogen Inc (NASDAQ:BIIB), Eledon Pharmaceuticals, Inc. (ELDN) and Neurocrine Biosciences Inc (NASDAQ:NBIX).
Oric Pharmaceuticals, Inc. is its number twenty one position by number of shares and market value among pharmaceuticals stocks.

Contrary to Orbimed Advisors, Alkeon Capital Management, California State Teachers Retirement System, and Citigroup (NYSE:C) added to ORIC shares.